KFDA to review data exemption for combined drug registration.

The KFDA said in the brief talk meeting with the pharmaceutical companies of developing a combined anti-diabetic drug that the standards required for the combined drug registration data should be wholly reviewed to an effect that 4 data including general pharmacological study data for a combined anti-diabetic drug may not be necessary to submit when reviewing its clinical study approval and eff...